These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 25885600)

  • 1. Inhibition of SHP2 in basal-like and triple-negative breast cells induces basal-to-luminal transition, hormone dependency, and sensitivity to anti-hormone treatment.
    Zhao H; Agazie YM
    BMC Cancer; 2015 Mar; 15():109. PubMed ID: 25885600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.
    Matalkah F; Martin E; Zhao H; Agazie YM
    Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SHP2 Potentiates the Oncogenic Activity of β-Catenin to Promote Triple-Negative Breast Cancer.
    Martin E; Agazie YM
    Mol Cancer Res; 2021 Nov; 19(11):1946-1956. PubMed ID: 34389690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells.
    Zhou XD; Agazie YM
    Cell Death Differ; 2008 Jun; 15(6):988-96. PubMed ID: 18421299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
    Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
    Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
    Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SHP2 positively regulates TGFβ1-induced epithelial-mesenchymal transition modulated by its novel interacting protein Hook1.
    Li S; Wang L; Zhao Q; Liu Y; He L; Xu Q; Sun X; Teng L; Cheng H; Ke Y
    J Biol Chem; 2014 Dec; 289(49):34152-60. PubMed ID: 25331952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis.
    Zhou X; Coad J; Ducatman B; Agazie YM
    Histopathology; 2008 Oct; 53(4):389-402. PubMed ID: 18643929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Network Analysis Identifies Regulators of Basal-Like Breast Cancer Reprogramming and Endocrine Therapy Vulnerability.
    Choi SR; Hwang CY; Lee J; Cho KH
    Cancer Res; 2022 Jan; 82(2):320-333. PubMed ID: 34845001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
    Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
    FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Salivary gland-like tumors of the breast express basal-type immunohistochemical markers.
    Reyes C; Jorda M; Gomez-Fernández C
    Appl Immunohistochem Mol Morphol; 2013 Jul; 21(4):283-6. PubMed ID: 22935826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Shp2 Plays a Critical Role in IL-6-Induced EMT in Breast Cancer Cells.
    Sun X; Zhang J; Wang Z; Ji W; Tian R; Zhang F; Niu R
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
    Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
    Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The tyrosine phosphatase SHP2 regulates focal adhesion kinase to promote EGF-induced lamellipodia persistence and cell migration.
    Hartman ZR; Schaller MD; Agazie YM
    Mol Cancer Res; 2013 Jun; 11(6):651-64. PubMed ID: 23512980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop.
    Aceto N; Sausgruber N; Brinkhaus H; Gaidatzis D; Martiny-Baron G; Mazzarol G; Confalonieri S; Quarto M; Hu G; Balwierz PJ; Pachkov M; Elledge SJ; van Nimwegen E; Stadler MB; Bentires-Alj M
    Nat Med; 2012 Mar; 18(4):529-37. PubMed ID: 22388088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High CD90 (THY-1) expression positively correlates with cell transformation and worse prognosis in basal-like breast cancer tumors.
    Lobba ARM; Carreira ACO; Cerqueira OLD; Fujita A; DeOcesano-Pereira C; Osorio CAB; Soares FA; Rameshwar P; Sogayar MC
    PLoS One; 2018; 13(6):e0199254. PubMed ID: 29949609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.
    van Geldermalsen M; Wang Q; Nagarajah R; Marshall AD; Thoeng A; Gao D; Ritchie W; Feng Y; Bailey CG; Deng N; Harvey K; Beith JM; Selinger CI; O'Toole SA; Rasko JE; Holst J
    Oncogene; 2016 Jun; 35(24):3201-8. PubMed ID: 26455325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein tyrosine phosphatase SHP2 promotes invadopodia formation through suppression of Rho signaling.
    Tsai WC; Chen CL; Chen HC
    Oncotarget; 2015 Sep; 6(27):23845-56. PubMed ID: 26204488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shp2 negatively regulates growth in cardiomyocytes by controlling focal adhesion kinase/Src and mTOR pathways.
    Marin TM; Clemente CF; Santos AM; Picardi PK; Pascoal VD; Lopes-Cendes I; Saad MJ; Franchini KG
    Circ Res; 2008 Oct; 103(8):813-24. PubMed ID: 18757826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential expression of epithelial–mesenchymal transition and stem cell markers in intrinsic subtypes of breast cancer.
    Pomp V; Leo C; Mauracher A; Korol D; Guo W; Varga Z
    Breast Cancer Res Treat; 2015 Nov; 154(1):45-55. PubMed ID: 26467042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.